Ipsen’s U.S. Business Could Be Profitable In 2016, A Year Early
This article was originally published in The Pink Sheet Daily
Executive Summary
A turnaround in Ipsen’s U.S. business is underpinning a transformation at the European mid-sized pharmaceutical company, which is planning to narrow its focus to niche therapeutic areas including gastrointestinal endocrine tumors and antispasticity neurotoxins.